{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:50:37.914510",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 54,
    "temperature": 0.2
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "durvalumab with tremelimumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5764
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial chemoembolization",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radioactive Iodine 131 treatment",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "hormonal therapy with tamoxifen",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "subcutaneous octreotide therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5682
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "durvalumab with tremelimumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who have not received durvalumab in the first line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5764
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients treated with SIRT",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 3686
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 20,
      "ContextTokens": 4528
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "PICOs": [],
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma previously treated with sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab plus ipilimumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "transarterial chemoembolization (TACE)",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "selective internal radiation therapy (SIRT)",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 7317
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "patients with advanced HCC, who have failed or are not eligible for local-regional therapy, with impaired hepatic function (Child-Pugh B)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/or unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "FOLFOX4",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/or unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "doxorubicin",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5569
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab with bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma who had not received previous systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 6031
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "combination of bevacizumab and atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucyrumab",
          "Outcomes": ""
        },
        {
          "Population": "patients who are well tolerant of sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "leninivat",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 15,
      "ContextTokens": 3401
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tremelimumab-durvalumab combination",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 4290
    }
  }
}